To the contrary, less than 20% of recipients of splenocytes from mice treated either with IL-2:mAb complexes or IL-2:mAb complexes together with tetramers (combined optimized treatment) succumbed to T1D (Fig. 6C). This evidence concerns the gene IL2 and type 1 diabetes mellitus.